Approval and Launch of New Drugs and R&D of New Therapies to Augment Growth of Cystinosis Treatment Market
Cystinosis is an inflammatory condition characterized by excess accumulation of the harmful amino acid casein (a building block of amino acids) in tissues and organs. Excessive cystinosis often forms crystals that can settle into tissues and organs and cause serious problems in many bodily systems and organs. It is also accompanied by low red blood cell count, increased blood pressure, and headaches. In most patients, cystinosis clears after several years. The condition is usually inherited and develops slowly over time. Market Dynamics Approval and launch of new drugs is expected to propel the growth of the cystinosis treatment market . For instance, in March 2020 AVROBIO, Inc. received the U.S. Food and Drug Administration’s orphan drug designation for its investigational gene therapy, AVR-RD-04, for the treatment of cystinosis. R&D of new therapies is expected to offer lucrative growth opportunities for players in the cystinosis treatment market. For instance, i...